摘要
尽管对列腺癌(PCA)的早期诊断取得了相当大的进展,但在西方国家,前列腺癌(PCA)任是因癌症导致死亡的第二大原因。事实上,由于其对抗癌药物的反应性差,在疾病的早期阶段,虽然存在有效的治疗方法,但对晚期前列腺癌的治疗却十分有限。这些都表明迫切需要寻求新的和更有效的治疗方法。microRNAs是一种短的非编码RNA,它能通过转录后水平调控PCA细胞的基因表达,microRNAs的失调和其同时调节多种致癌/抑癌途径的潜力,引起了人们对特定miRNA表达的改变以及PCA对抗癌药物的反应的功能之间关系的兴趣。本文对PCA相关miRNA作为潜在的新型治疗靶点/工具,和其在调节PCA对抗癌药物的反应发挥的作用进行了归纳总结。
关键词: 抗肿瘤药物,microRNA,前列腺癌。
图形摘要
Current Drug Targets
Title:MicroRNAs and the Response of Prostate Cancer to Anti-Cancer Drugs
Volume: 17 Issue: 3
Author(s): Marzia Pennati, Marco Folini, Paolo Gandellini and Nadia Zaffaroni
Affiliation:
关键词: 抗肿瘤药物,microRNA,前列腺癌。
摘要: Despite considerable advances in early diagnosis, prostate cancer (PCa) remains the second leading cause of cancer-related deaths in men in western countries. In fact, although efficient therapies exist for early-stage disease, the treatment of advanced PCa remains unsuccessful mainly due to its poor responsiveness to anti-cancer agents. This evidence underlines the urgent need for the development of novel and more effective therapeutic approaches. In this context, the documented dysregulation of microRNAs (miRNAs) -which are short non-coding RNAs that regulate gene expression at post-transcriptional level- in PCa, together with their potential to simultaneously regulate multiple oncogenic/ tumor-suppressive pathways, has stimulated interest in defining a functional association between altered expression of specific miRNAs and the response of PCa to anti-cancer agents. The purpose of this review is to provide an overview on PCa-related miRNAs as potential novel therapeutic targets/tools, with a special focus on the role that they may play in conditioning the responsiveness of PCa to anti-cancer drugs.
Export Options
About this article
Cite this article as:
Marzia Pennati, Marco Folini, Paolo Gandellini and Nadia Zaffaroni , MicroRNAs and the Response of Prostate Cancer to Anti-Cancer Drugs, Current Drug Targets 2016; 17 (3) . https://dx.doi.org/10.2174/1389450116666150316223341
DOI https://dx.doi.org/10.2174/1389450116666150316223341 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pancreatic Cancer and Personalized Medicine: Can Genomics Facilitate Early Diagnosis or Improve Therapeutic Outcomes?
Current Pharmacogenomics and Personalized Medicine Dendrimer-Curcumin Conjugate: A Water Soluble and Effective Cytotoxic Agent Against Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Pharmacokinetics and Disposition of Nanomedicine Using Biodegradable PEG/PCL Polymers as Drug Carriers
Current Drug Metabolism Review of the Biological Activity of Maslinic Acid
Current Drug Targets Soy Saponins and the Anticancer Effects of Soybeans and Soy-Based Foods
Current Medicinal Chemistry - Anti-Cancer Agents Evasion of Ribonuclease Inhibitor as a Determinant of Ribonuclease Cytotoxicity
Current Pharmaceutical Biotechnology Thymulin: An Emerging Anti-Inflammatory Molecule
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Ionic Liquids, Microextraction Methods and Capillary Electrophoresis in Biomedical Research
Current Pharmaceutical Analysis Applications of High Content Screening in Life Science Research
Combinatorial Chemistry & High Throughput Screening Synthesis, Anticancer Screening and Molecular Docking Studies of New Heterocycles with Trimethoxyphenyl Scaffold as Combretastatin Analogues
Mini-Reviews in Medicinal Chemistry Adrenomedullin and Nitric Oxide: Implications for the Etiology and Treatment of Primary Brain Tumors
CNS & Neurological Disorders - Drug Targets Novel Inhibitors of Inosine Monophosphate Dehydrogenase in Patent Literature of the Last Decade
Recent Patents on Anti-Cancer Drug Discovery Glucagon and Glucagon-Like Peptide Receptors as Drug Targets
Current Pharmaceutical Design MicroRNA Therapeutics in Neurological Disease
Current Pharmaceutical Design Targeting Histone Deacetylases for the Treatment of Immune, Endocrine & Metabolic Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System
Current Cancer Drug Targets A Role for the Inflammatory Mediators Cox-2 and Metalloproteinases in Cancer Stemness
Anti-Cancer Agents in Medicinal Chemistry H3K4 Methylation Status and Lysine Specific Methyltransferase KMT2C Expression Correlate with Prognosis in Lung Adenocarcinoma
Current Molecular Pharmacology Cancer Stem Cells Switch on Tumor Neovascularization
Current Molecular Medicine Subject Index Volume 6
Mini-Reviews in Medicinal Chemistry